Related coverage linked through entity extraction aliases.
Mar 16, 2026
Eli Lilly is preparing for the launch of oral weight loss pill Orforglipron with a US$3 billion, decade-long investment in China, while advancing its oncology and genetic medicine pipeline with positive Phase 3 results for Retevmo and a milestone in CRISPR collaboration.
Mar 14, 2026
AbbVie shares declined 2% on March 13, 2026, amid reduced trading volume, while BMO Capital maintained its Outperform rating following Phase 1 obesity drug trial data for ABBV-295.
Mar 14, 2026
The Trump administration launched TrumpRx on Feb. 5, a prescription drug website that displays discounted prices on 43 brand-name medications for out-of-pocket purchasers without insurance coverage.
Mar 13, 2026
The blood-brain barrier continues to block most treatments for glioblastoma and central nervous system diseases, with only 0.01% of biologic drugs reaching the brain. New intellectual property coverage and synthetic methods aim to address delivery challenges.
Mar 12, 2026
India's pharmaceutical industry, valued at Rs. 5.41 lakh crore in 2025, is transitioning from a generics powerhouse to an innovation-driven sector focused on biosimilars, complex formulations, and global R&D capabilities.
Mar 12, 2026
The global precision medicine market reached $82.1 billion in 2025 and is expected to grow to $179.4 billion by 2034. Researchers emphasize that precision nutrition interventions must demonstrate cost-effectiveness to deliver patient benefits.
Mar 12, 2026
New research from 18 countries shows COVID-19 vaccination during pregnancy, particularly with booster doses, significantly reduces the risk of preeclampsia and other serious complications for both mothers and babies.
Mar 12, 2026
New market reports forecast significant expansion in CAR T-cell therapy, US pharmaceutical drug delivery, and healthcare nanotechnology sectors, driven by chronic disease prevalence and technological advances.
Mar 10, 2026
AstraZeneca won a Federal Court injunction blocking Pharmacor from selling generic dapagliflozin products in Australia until a full patent trial. The patent expires October 22, 2027.
Mar 09, 2026
Eli Lilly's weight-loss drug Mounjaro fueled sevenfold sales growth in Brazil and doubled sales in India within months of launch, as the company commits $1 billion to make India a global export hub for its supply chain.
Mar 09, 2026
Sequel Med Tech and Senseonics announced full U.S. availability of the twiist Automated Insulin Delivery System integrated with the Eversense 365 CGM, the world's only one-year continuous glucose monitor, for people with type 1 diabetes.
Mar 08, 2026
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Mar 08, 2026
Novo Nordisk struggles against Eli Lilly in the weight loss market as CagriSema underperforms Zepbound, though new candidate UBT251 shows promise with 19.7% weight loss in 24 weeks. The company expects sales to decline in 2026 despite oral Wegovy's success.
Mar 07, 2026
Scientists at UCL have discovered that the protein LRG1 triggers the earliest damage in diabetic retinopathy by constricting retinal blood vessels. Blocking LRG1 in diabetic mice prevented early retinal damage and preserved normal eye function.
Mar 06, 2026
New research links GLP-1 drugs like Ozempic to increased scurvy risk through appetite suppression and poor nutrition. University of Florida researchers are testing a GLP-1 implant for obese cats as feline obesity affects nearly 60% of US cats.
Mar 06, 2026
New research reveals how GLP-1 receptor agonists promote pancreatic health through gene expression changes and interact bidirectionally with gut microbiome, while real-world users report unexpected lifestyle changes alongside weight loss.
Mar 05, 2026
The global biosimilar market is experiencing robust growth, valued at USD 36.79 billion in 2024 and projected to reach USD 282.3 billion by 2035 at a CAGR of 20.35%, driven by patent expirations, cost pressures, and expanding access to biologic therapies.
Mar 05, 2026
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
Mar 05, 2026
A large study of over 600,000 U.S. veterans with type 2 diabetes found GLP-1 medications reduced the risk of developing substance use disorders by 14% and cut drug-related deaths by 50% in those with existing addiction.
Mar 04, 2026
A new study suggests 7 hours and 18 minutes of sleep may be optimal for reducing insulin resistance risk. The research found an inverted U-shaped relationship between sleep duration and glucose metabolism, with weekend catch-up sleep showing mixed effects.
